Friday, September 29, 2023

561.316.3330

Biotechnology News Magazine

ENPICOM Launches Versatile Display Aata Analysis Solution to Accelerate Antibody Selection While Maximizing Precision

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

ENPICOM, an innovative bioinformatics software company, announced the upcoming expansion of the capabilities of the IGX Platform to unlock seamless analysis of antibody panning data.

This major development will allow researchers to analyze antibody display data in an intuitive and visual way, easily perform multi-dataset comparisons, and identify a diverse set of enriched candidates with the best characteristics.

“Our customer-centric approach to product development gives us a close-up view of the complex analysis workflows required for antibody display screening and how a single, scalable tool can immensely improve speed of analysis and quality of the selected candidates.” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM. “Due to limited, inefficient workflows researchers often have to discard the vast majority of the available NGS data and focus on a small pool of the most frequent clones. We are launching the new IGX-Track App so that our customers can look beyond the tip of the iceberg and make informed decisions with a complete view of their data. Custom analysis workflows and visualizations can be created with a few clicks so scientists can simply select better antibodies faster.”

Enabling streamlined enrichment analysis

Display technologies empower antibody discovery by screening millions of candidates against potential targets. By including different panning round conditions and a variety of antigens, researchers can obtain a robust candidate pool with diverse binding profiles. However, complex analysis workflows – including operations like intersecting, joining, or subtracting datasets – that match the panning campaign design are needed to fully take advantage of the powerful combination of NGS and display screening.

The new IGX-Track App extends the antibody discovery capabilities of the IGX Platform and provides a fast, flexible way to discover a diverse set of enriched candidates with the best characteristics. Scientists can effortlessly compose enrichment analysis workflows that match the design of their panning campaigns and discover candidates that otherwise would have been overlooked.

Scientists using IGX-Track on the IGX Platform will be able to:

  • Track clones across panning rounds to identify highly enriched candidates through tabular views and interactive, user-defined visualizations.
  • Freely join, intersect, and subtract many datasets to match their panning campaign design.
  • Broaden their analysis beyond just the most frequent clones with the platform’s scalable, NGS-ready architecture.
  • Easily subtract irrelevant antibodies identified in control panning conditions from the candidates enriched on target.
  • Make fully informed choices, while avoiding bias, by overlaying accurate liability predictions, assay data, and more onto enrichment graphs.

The company will launch the new functionality at the Antibody Engineering and Therapeutics conference on June 8 in Amsterdam. Sign up here to watch their presentation and learn more.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine